Our results showed that the binding level of RFX1 in the MCP1 gene promoter in CAD patients was reduced significantly, which decreased the enrichments of HDAC1 and SUV39H1, therefore leading to overexpression of MCP1 by downregulating histone H3 and H4 acetylation and upregulating H3K9 tri-methylation in the promoter region of the MCP1 gene. This evidence concerns the gene RFX1 and coronary artery disorder.